Form 4: Amylyx Pharmaceuticals CFO James Frates Acquires Shares and Stock Options

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports acquisition of 40,000 shares of common stock and 60,000 stock options.

Summary

• James M. Frates, the CFO of Amylyx Pharmaceuticals, reported acquiring 40,000 shares of common stock on February 26, 2024, at a price of $0.00 per share.
• These shares were received as a restricted stock unit (RSU) award, vesting in four equal annual installments starting one year from the grant date, contingent upon continued service.
• Frates also acquired 60,000 stock options with an exercise price of $17.56, also on February 26, 2024.
• These options vest over 48 months, with 1/4 vesting after one year and the remainder vesting monthly thereafter, also contingent upon continued service.
• Following these transactions, Frates directly owns 152,035 shares of common stock and 60,000 stock options.
• He also indirectly owns 11,072 shares through the FRATES FAMILY 2013 IRREV TRUST, for which he serves as trustee.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports transactions by a company insider, which is a routine occurrence. The acquisitions could be seen as a positive sign, but without further context, it's difficult to assign a strong positive sentiment.

Positives

• The acquisition of shares and stock options by the CFO could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSU and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The acquisition of shares and options by the CFO may have a minor positive impact on shareholder sentiment.

Key Dates